iTeos Therapeutics Names New Chief Medical Officer
| Field | Detail |
|---|---|
| Company | Iteos Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, cmo
TL;DR
iTeos CMO out, new CMO in. Atwood takes the helm.
AI Summary
On July 18, 2025, iTeos Therapeutics, Inc. announced the departure of Dr. Christophe Quéva from his role as Chief Medical Officer. The company also announced the appointment of Dr. Jennifer L. Atwood as the new Chief Medical Officer, effective immediately. Dr. Atwood previously served as Senior Vice President of Clinical Development at iTeos.
Why It Matters
A change in a key executive role like Chief Medical Officer can impact the company's strategic direction and the execution of its clinical development programs.
Risk Assessment
Risk Level: medium — Changes in key leadership can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- iTeos Therapeutics, Inc. (company) — Registrant
- Dr. Christophe Quéva (person) — Departing Chief Medical Officer
- Dr. Jennifer L. Atwood (person) — Newly appointed Chief Medical Officer
- July 18, 2025 (date) — Effective date of changes
FAQ
Who is the new Chief Medical Officer at iTeos Therapeutics?
Dr. Jennifer L. Atwood has been appointed as the new Chief Medical Officer, effective immediately.
When did the leadership change occur?
The changes were reported as of July 18, 2025.
Who previously held the Chief Medical Officer position?
Dr. Christophe Quéva previously served as the Chief Medical Officer.
What was Dr. Atwood's prior role at iTeos Therapeutics?
Dr. Atwood previously served as Senior Vice President of Clinical Development at iTeos Therapeutics.
What is the primary business of iTeos Therapeutics?
iTeos Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 by Dr. Christophe Quéva regarding iTeos Therapeutics, Inc..